AIPAC (Active Immunotherapy PAClitaxel): A phase IIb trial in hormone receptor-positive metastatic breast carcinoma patients receiving IMP321 (LAG-3Ig fusion protein) or placebo as adjunctive to a standard chemotherapy regimen of paclitaxel

Hormone Receptor Positive ◽

Standard Chemotherapy Regimen

A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel

Case Medical Research ◽

10.31525/ct1-nct04252768 ◽

2020 ◽

Author(s):

Keyword(s):

Breast Carcinoma ◽

Treatment Regimen ◽

Hormone Receptor ◽

Metastatic Breast ◽

Hormone Receptor Positive ◽

Weekly Treatment

Abstract OT1-01-05: AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cancer

10.1158/1538-7445.sabcs19-ot1-01-05 ◽

2020 ◽

Author(s):

Luc Dirix ◽

Hans Wildiers ◽

Manon T Huizing ◽

Eveline De Cuypere ◽

Carolina P Schröder ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Fusion Protein ◽

Hormone Receptor ◽

Metastatic Breast ◽

Active Immunotherapy ◽

Double Blind ◽

Double Blind Placebo ◽

Hormone Receptor Positive

AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps1109 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS1109-TPS1109

Author(s):

Luc Dirix ◽

A. Jager ◽

Frederik Marme ◽

Etienne Brain ◽

Anne Caroline Armstrong ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Fusion Protein ◽

Hormone Receptor ◽

Metastatic Breast ◽

Active Immunotherapy ◽

Double Blind ◽

Double Blind Placebo ◽

Hormone Receptor Positive

Hormone Receptor Assessment of Metastatic Breast Carcinoma by Fine Needle Aspiration Utilizing Cell Blocks and Cell Transfer Techniques: An Immunocytochemical Review of 291 Consecutive Cases

Journal of the American Society of Cytopathology ◽

10.1016/j.jasc.2016.07.020 ◽

2016 ◽

Vol 5 (5) ◽

pp. S10

Author(s):

Megan Alderman ◽

Howard Wu

Keyword(s):

Breast Carcinoma ◽

Fine Needle Aspiration ◽

Hormone Receptor ◽

Metastatic Breast ◽

Needle Aspiration ◽

Cell Transfer ◽

Fine Needle ◽

Abstract 2574: Interleukin-7 (CYT107) treatment in lymphopenic 1st line metastatic breast carcinoma patients treated with chemotherapy regimen (Capecitabine) favors the restoration of T-cell subsets number

10.1158/1538-7445.am2014-2574 ◽

2014 ◽

Author(s):

Christine Menetrier-Caux ◽

Isabelle Ray-Coquard ◽

Claire Cropet ◽

Estelle Verronese ◽

Thomas Bachelot ◽

...

Keyword(s):

T Cell ◽

Breast Carcinoma ◽

Chemotherapy Regimen ◽

Metastatic Breast ◽

T Cell Subsets ◽

Interleukin 7

Discordance in Hormone Receptor Status of Primary Versus Metastatic Breast Carcinoma

Journal of the American Society of Cytopathology ◽

10.1016/j.jasc.2018.06.023 ◽

2018 ◽

Vol 7 (5) ◽

pp. S4-S5

Author(s):

Padmini Manrai ◽

Edwin Partovi ◽

Ying-Chun Lo ◽

Armine Darbinyan ◽

Marguerite Pinto ◽

...

Keyword(s):

Breast Carcinoma ◽

Hormone Receptor ◽

Metastatic Breast ◽

Hormone Receptor Status ◽

Receptor Status ◽

Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Final results from the run-in phase of a placebo-controlled randomized phase II.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.1050 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 1050-1050 ◽

Cited By ~ 5

Author(s):

Francois P. Duhoux ◽

Agnes Jager ◽

Luc Yves Dirix ◽

Manon Thirza Huizing ◽

Guy Heinrich Maria Jerusalem ◽

...

Keyword(s):

Breast Carcinoma ◽

Fusion Protein ◽

Phase Ii ◽

Metastatic Breast ◽

First Line ◽

Randomized Phase Ii

Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy

Cancer ◽

10.1002/1097-0142(20001201)89:11<2195::aid-cncr7>3.0.co;2-w ◽

2000 ◽

Vol 89 (11) ◽

pp. 2195-2201 ◽

Cited By ~ 18

Author(s):

Edgardo Rivera ◽

Frankie A. Holmes ◽

Debra Frye ◽

Vicente Valero ◽

Richard L. Theriault ◽

...

Keyword(s):

Breast Carcinoma ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Standard Chemotherapy ◽

Hormone Receptor Assessment of Metastatic Breast Carcinoma by Fine Needle Aspiration Utilizing Cell Blocks and Cell Transfer Techniques: An Immunocytochemical Review of 163 Consecutive Cases

Cytology & Tissue Biology ◽

10.24966/ctb-9107/100009 ◽

2016 ◽

Vol 3 (1) ◽

pp. 1-4 ◽

Cited By ~ 1

Author(s):

Howard H Wu ◽

Keyword(s):

Breast Carcinoma ◽

Fine Needle Aspiration ◽

Hormone Receptor ◽

Metastatic Breast ◽

Needle Aspiration ◽

Cell Transfer ◽

Fine Needle ◽

A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

Case Medical Research ◽

10.31525/ct1-nct04060862 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Hormone Receptor ◽

Locally Advanced ◽

Metastatic Breast ◽

Hormone Receptor Positive